In this iBrief, L. David Harlow, III, PharmD, assistant vice president for professional services and chief pharmacy officer at Martin Health System, offers his thoughts on how the passage of the 21st Century Cures Act will affect the pace of new drug and device approvals in 2017. He also offers advice to companies on what they can do to prepare in an uncertain political climate.